Healthcare of Ontario Pension Plan Trust Fund Boosts Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 318.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 372,900 shares of the company's stock after purchasing an additional 283,700 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned about 0.22% of Dr. Reddy's Laboratories worth $28,411,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Millennium Management LLC lifted its position in shares of Dr. Reddy's Laboratories by 61.4% in the 2nd quarter. Millennium Management LLC now owns 332,502 shares of the company's stock worth $25,333,000 after purchasing an additional 126,472 shares during the period. Schroder Investment Management Group lifted its holdings in Dr. Reddy's Laboratories by 77.6% in the fourth quarter. Schroder Investment Management Group now owns 266,653 shares of the company's stock worth $18,554,000 after buying an additional 116,488 shares during the period. Fisher Asset Management LLC boosted its position in Dr. Reddy's Laboratories by 126.5% during the 4th quarter. Fisher Asset Management LLC now owns 205,280 shares of the company's stock valued at $14,283,000 after acquiring an additional 114,630 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Dr. Reddy's Laboratories by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company's stock worth $76,455,000 after acquiring an additional 114,294 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Dr. Reddy's Laboratories by 2,197.8% in the 1st quarter. Jane Street Group LLC now owns 113,168 shares of the company's stock worth $8,301,000 after acquiring an additional 108,243 shares in the last quarter. Institutional investors own 14.02% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Barclays upped their price target on Dr. Reddy's Laboratories from $81.00 to $87.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 30th.

Dr. Reddy's Laboratories Stock Down 1.6 %

NYSE RDY traded down $1.30 during trading hours on Friday, reaching $78.27. 135,004 shares of the company's stock traded hands, compared to its average volume of 214,593. The firm has a market cap of $13.06 billion, a PE ratio of 19.67, a PEG ratio of 1.75 and a beta of 0.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.55 and a quick ratio of 1.90. Dr. Reddy's Laboratories Limited has a 52-week low of $63.72 and a 52-week high of $84.46. The firm has a 50-day simple moving average of $81.15 and a 200 day simple moving average of $75.95.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Saturday, July 27th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.10). Dr. Reddy's Laboratories had a return on equity of 20.32% and a net margin of 19.28%. The company had revenue of $919.80 million during the quarter, compared to analysts' expectations of $861.68 million. Sell-side analysts anticipate that Dr. Reddy's Laboratories Limited will post 4.11 EPS for the current fiscal year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.